Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later - sprookjes - yvandenbroek - TriplyDB

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

http://www.wikidata.org/entity/Q24606321

about

Psychedelics and mental health: a population study Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Recent advances in the neuropsychopharmacology of serotonergic hallucinogens Psychedelics LSD enhances the emotional response to music.LSD-induced entropic brain activity predicts subsequent personality change.Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin Peak experiences of psilocybin users and non-users.Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.Alterations of consciousness and mystical-type experiences after acute LSD in humans.Resorcylic acid lactones with cytotoxic and NF-κB inhibitory activities and their structure-activity relationships Therapeutic infusions of ketamine: do the psychoactive effects matter?Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.The god within.Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes.The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories.Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists.Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Neuropharmacology of N,N-dimethyltryptamine Clinical applications of hallucinogens: A review.Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD).Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)Neurotheology-Matters of the Mind or Matters that Mind?Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases.Role of psilocybin in the treatment of depression.Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.Psychobiology of drug-induced religious experience: from the brain "locus of religion" to cognitive unbinding.Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses.Health status of ayahuasca users.Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin.

P2860

Q21089784-F158FAE4-C7BF-466B-8E57-8FDC228687B4 Q21091087-130B1869-1DC7-4DF6-A45C-4254E2D60F01 Q21129387-58B22D13-B36C-4BCB-946F-F2DC8E1338B1 Q22241778-9C9665D7-8B41-4449-BED3-D180BA9AFF84 Q24613764-ED7A8F90-559A-4036-8F53-CEE410329923 Q24633222-4796E7FD-1ABE-4D99-A619-662530E8FA34 Q24634013-A281BA10-BD9F-43A4-B3E8-1FFE5E37AECF Q26746137-4C52B3CB-823A-459A-8A19-1E70D820184C Q27027381-41248BCF-8DE3-4310-B862-D634C644D23E Q30359998-405250CC-B8E1-4131-853C-C4F4DFD701E5 Q30377709-17F1EDBD-235C-4824-9BF2-81D592EF5330 Q30387757-12A36F36-9D1D-4C50-B20C-A05BA3AA214B Q30531761-E2762554-9A7C-4140-9860-C9509F9B6323 Q30559498-D69820D0-C8CC-4089-A733-667921DF6B18 Q30833479-07931095-4A76-450B-B1EF-9E026185B0ED Q30843010-74F6D1C8-EB93-4C7E-8E0C-2CDE38261E1B Q30847957-1EBB6F3A-7EE0-4088-B5DF-DB0FC125895F Q33879712-50DAE605-A828-4888-A2D7-A7722A7D55CA Q33880853-BACCC4B2-E085-4C26-828D-D80EE6BF838F Q33937677-33524534-6C3A-4F1A-97AD-3D868AEA3328 Q34027387-F54C527F-CE74-452F-BD6D-00F42842F00F Q34178760-FD8F73A5-0870-4381-833A-E15C791DEB92 Q34325119-1981B3EB-AF25-4AEE-948C-CD1F4F4A0A18 Q34392399-32580FFE-75E2-42EF-996E-AEF318685C98 Q34396223-4FB05CAD-382D-4D50-8C6C-22ECCC747B0D Q34438146-9A270B72-02CA-48D1-874B-17BDFDA7F2F2 Q34524116-0A82E994-8775-42C3-AA97-A6D8C91DD9B7 Q34535259-B8DCDDEA-75C1-4176-A870-D57CADC92A1E Q35126018-89C26E3B-6FCD-4A70-B5EB-FEEF21824A93 Q35737157-AFE40FAE-56CD-4B53-B47F-104CD0A5B260 Q35936959-4A99636F-35A6-4BBD-ABA8-4FC1E219579D Q36999815-12BA2886-9753-4B55-B4DC-D35F1878DF43 Q37111409-2731A8CA-595F-4D6D-A766-C0DD6B52836F Q37464848-538574DA-A12F-4DC2-A63C-166837ABE803 Q37582715-B067D457-B33A-48E6-9CFB-0A7B513B5492 Q37722650-9C9DEB15-2879-4DF6-8EED-F23F0B8D2DA5 Q37730083-032C24D2-472B-4DF7-B48A-24A680677052 Q38023813-E61069D6-CE72-4B05-9DB9-8F3F8E25A5FB Q38023821-56247128-5A5D-43CA-8033-F5B0B907B8F7 Q38061522-26B6EECD-8FE3-43FD-8365-750AA6ADBE61

P2860

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

http://www.wikidata.org/entity/Q24606321

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Mystical-type experiences occa ...... l significance 14 months later

@ast

Mystical-type experiences occa ...... l significance 14 months later

@en

Mystical-type experiences occa ...... l significance 14 months later

@nl

type

label

Mystical-type experiences occa ...... l significance 14 months later

@ast

Mystical-type experiences occa ...... l significance 14 months later

@en

Mystical-type experiences occa ...... l significance 14 months later

@nl

prefLabel

Mystical-type experiences occa ...... l significance 14 months later

@ast

Mystical-type experiences occa ...... l significance 14 months later

@en

Mystical-type experiences occa ...... l significance 14 months later

@nl

P1433

Q24606321-470CA10D-2ABE-4B40-A757-AF439D9FEE9C

P1476

Q24606321-4BE8F56F-5741-4C95-B936-17FCE401F0C4

P2093

Q24606321-7B59CE0A-2EF3-4E5D-BCA2-2C2DC9391225

Q24606321-7C68A7D3-11A1-49CF-B55E-5AD6D596AA6E

Q24606321-A2F4D488-B83C-4D15-B03F-9007E8210A81

Q24606321-B76A6F25-542F-46AF-8334-2481965275C3

Q24606321-C4B47BBB-D7C1-42D2-8676-8414B4DC74AC

P2860

Q24606321-0D49B792-3C25-4C85-AE2C-1B7BCE6CF35B

Q24606321-285E3725-4D94-4B1A-93B4-9261B08263B2

Q24606321-34AF8DF1-1AE7-4FEA-9FE3-0128BE626EA4

Q24606321-38D8B4EB-6021-4C04-B20F-2793A46F9B1D

Q24606321-408A5E76-6EFA-4097-9403-B8B5869A9838

Q24606321-5FC16875-4CA7-4749-9F52-61BF39A6CE70

Q24606321-6EF3566F-859E-48CB-B72A-629DFCE4E12D

Q24606321-795FC999-08D7-4172-8B77-D9B919DF642A

Q24606321-8BE6E6B0-12D0-46B1-B118-CC5D8B4D5403

Q24606321-9C38023E-9B49-49DA-9847-21E1B9609456

P304

Q24606321-54C6229F-5032-487F-A884-B9794E7ACFCC

P31

Q24606321-3FCC13B1-17F6-4FB3-B06B-3FD441333935

P3181

Q24606321-9263E559-EC3E-4F4F-A319-1C8FD774176A

P356

Q24606321-509862E0-C5D5-4057-AF4C-E5ECB3DF0C98

P407

Q24606321-E940C8EF-ABAB-44FA-8D51-7F072CE0D146

P433

Q24606321-E955493C-6785-4C72-ADC0-1D15E688F8FF

P478

Q24606321-14A5EBB8-1590-499A-AC33-B39F487E7CAC

P577

Q24606321-7555E5AD-9C16-4E41-A5BF-C9FB5609E324

P5875

Q24606321-7D3A2390-8D32-4D7C-BE9D-0B326CE354CB

P698

Q24606321-E5ABDB63-9DCB-420C-9063-A589359D3FB1

P932

Q24606321-A447AFCC-CEDB-478E-B081-3A75A370AB22

P3181

P356

0269881108094300

P1433

Journal of Psychopharmacology

P1476

Mystical-type experiences occa ...... l significance 14 months later

@en

P2093

Mw Johnson

http://www.w3.org/2001/XMLSchema#string

R Jesse

http://www.w3.org/2001/XMLSchema#string

Rr Griffiths

http://www.w3.org/2001/XMLSchema#string

Ud McCann

http://www.w3.org/2001/XMLSchema#string

Wa Richards

http://www.w3.org/2001/XMLSchema#string

P2860

Human hallucinogen research: guidelines for safety

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Do hallucinogens cause residual neuropsychological toxicity?

Use of d-lysergic acid diethylamide in the treatment of alcoholism.

REACTIONS TO PSILOCYBIN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT.

Some observations on psilocybin, a new hallucinogen, in volunteer subjects.

Experimental psychiatry. V. Psilocybine, a new psychotogenic drug.

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.

Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.

P304

621-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

812205

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/0269881108094300

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5259183

http://www.w3.org/2001/XMLSchema#string

P698

18593735

http://www.w3.org/2001/XMLSchema#string

P932

3050654

http://www.w3.org/2001/XMLSchema#string